NCT06778213View on ClinicalTrials.gov

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 2, 2024

Primary Completion Date

April 2, 2026

Study Completion Date

December 1, 2026

Conditions

Allergic Rhinoconjunctivitis

Interventions

BIOLOGICAL

NovoHelisen Depot

allergen immunotherapy treatment for 12 months with house dust mite allergen preparation

Trial Locations (1)

53-201

RECRUITING

ALL-MED Medical Research Institute, Wroclaw

All Listed Sponsors

collaborator

ALL-MED Medical Research Institute, Wroclaw, Poland

UNKNOWN

collaborator

Allergopharma GmbH & Co. KG

INDUSTRY

lead

Wroclaw Medical University

OTHER

NCT06778213 - Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study | Biotech Hunter | Biotech Hunter